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Inflammation and reduced albumin synthesis associated with
stable decline in serum albumin in hemodialysis patients.
Background. The concentration of albumin in serum is main-
tained by its rates of synthesis, catabolism, and distribution
between vascular and extravascular compartments. Albumin
synthesis is suppressed when there is inflammation or inad-
equate protein intake. This study was conducted to establish
whether a decline in serum albumin of >0.3 g/dL was accompa-
nied by a change in albumin synthesis and if so whether these
changes were associated with increased levels of acute phase
proteins and/or with a decrease in equilibrated normalized pro-
tein catabolic rate (enPCR).
Methods. Seventy-nine patients in the National Institutes
of Health (NIH)-sponsored HEMO Study had baseline mea-
surements of albumin synthesis (measured kinetically as the
disappearance of [125]I human serum albumin), the serum con-
centrations of albumin, transferrin, C-reactive protein (CRP),
a1 acid glycoprotein (a1AG), ceruloplasmin, interleukin-6
(IL-6), plus monthly measurements of enPCR. The plasma lev-
els of all proteins and enPCR were measured regularly over
2 years or until serum albumin decreased by >0.3 g/dL on two
sequential measurements. Albumin synthesis was measured a
second time when serum albumin declined by >0.3 g/dL or after
2 years.
Results. Fifty-nine patients [21 with a significant decrease in
serum albumin (decliners) and 38 with stable values of serum
albumin] had albumin synthesis measured twice. A decline in
albumin concentration and synthesis was associated with an in-
crease in a1AG when data from all patients were analyzed as
a group. In decliners, albumin synthesis decreased significantly
but was unchanged in stable. Likewise, in decliners, IL-6, CRP,
a1AG, and ceruloplasmin increased significantly but were un-
changed in stable. enPCR was unchanged in both groups and
was not associated with either changes in albumin level or syn-
thesis in the whole group.
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Conclusion. A decrease in serum albumin of >0.3 g/dL that
persists for a period of 6 weeks is associated a decrease in al-
bumin synthesis. This response is associated with evidence of
activation of the acute phase response (inflammation) but not
with changes in enPCR. In well-dialyzed patients, inflamma-
tion is the principal cause of a decrease in serum albumin while
protein intake plays an insignificant role.
Serum albumin concentration is a powerful predictor
of survival in patients with renal failure [1]. The con-
centration of albumin in serum is determined not only
by dilution but also by its rate of synthesis, its fractional
catabolic rate (FCR), its dilution within the plasma com-
partment and its partitioning between the vascular and
extravascular pool. These processes are in turn controlled
by a multiplicity of factors, including nutritional [2, 3], in-
flammation [4], gender [5], and age [6], although the de-
cline in serum albumin associated with aging may also
be related to other factors [7, 8]. We established that
serum albumin concentration is quite variable in dialy-
sis patients [9]. It is known that a low serum albumin is
associated with an increase in the positive acute phase
protein, C-reactive protein (CRP). Changes in serum al-
bumin concentration that persist over periods of time that
approach the half-life albumin, 14 to 21 days [10–12], are
likely to reflect changes in albumin pool sizes and alter-
ations in albumin synthesis or catabolism. To investigate
the mechanisms responsible for a long-lived decline in
serum albumin of >0.3 g/dL and how these mechanisms
are associated with demographic, nutritional, and inflam-
matory indicators we measured longer-lived acute phase
reactant proteins [ceruloplasmin and a1 acid glycopro-
tein (a1AG)] as the level of these proteins predicts sub-
sequent changes in serum albumin [13].
Another mechanism for a decrease in serum albumin
is a poor diet. In children with protein-calorie malnutri-
tion serum albumin declines and some have found that a
poor intake of protein (based on dietary records or urea
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kinetic modeling) is independently associated with a low
serum albumin [14]. On the other hand, hypoalbumine-
mia does not occur without extreme food deprivation
in the absence of inflammation [3, 15]. Indeed, Rigaud
et al [3] found that serum levels of albumin and prealbu-
min were essentially normal in otherwise healthy women
with anorexia nervosa. To investigate these associations,
we evaluated whether changes in serum albumin could be
linked to a change in the levels of acute phase reactant
proteins, equilibrated normalized protein catabolic rate
(enPCR) or in both variables in a group of patients re-
ceiving standardized dialysis treatment while participat-
ing in the National Institutes of Health (NIH)-sponsored
HEMO Study [16].
METHODS
Patient selection
The individual Institutional Review Boards at each in-
stitution approved the protocol and informed consent
was obtained from each patient. Seventy-nine patients
enrolled in the NIH HEMO Study at the University of
California Davis in Sacramento, California, at Beth Israel
Medical Center in New York, New York, and at Emory
University in Atlanta, Georgia, were recruited to partic-
ipate in a longitudinal study of the relationship between
the levels of acute phase proteins and serum albumin
concentration. All patients who had been randomized
into one of the four HEMO treatment groups were el-
igible for enrollment in this study. Inclusion criteria for
the HEMO Study require that the patient be between 18
and 80 years of age, receive in-center hemodialysis three
times per week, and have been on dialysis for at least
3 months. Exclusion criteria include a urine urea clear-
ance of >1.5 mL/min/35 L urea volume; the presence of
serious comorbid medical conditions such as active ma-
lignancies requiring chemotherapy or radiation therapy,
treated class IV congestive heart failure, unstable angina
pectoris, symptomatic AIDS, active systemic infections
such as tuberculosis or systemic fungal infection, chronic
pulmonary disease requiring supplemental oxygen, and
cirrhosis with encephalopathy or abnormal prothrombin
time; and scheduled living donor transplant within the
period of the study. Additionally, we required that the
patients be able and willing to come to the Clinical Re-
search Center or nuclear medicine unit on a nondialysis
day for injection of [125]I human albumin and for collec-
tion of the initial blood samples.
The design of the study was to measure albumin syn-
thesis and distribution at the onset of the study and at
the same time to measure the levels of the cytokine
interleukin-6 (IL-6), the positive acute phase proteins
CRP, a1AG, ceruloplasmin, and the negative acute phase
protein transferrin. Blood was drawn both pre- and post-
dialysis for analysis of albumin as described previously
[17]. Following these measures both serum and plasma
was obtained monthly. If the serum albumin concentra-
tion decreased by more than 0.3 g/dL compared to the
mean value obtained during the initial 6 weeks of ob-
servation, a second sample of serum was analyzed to es-
tablish whether the decrease in albumin concentration
persisted. The second measurement was made within
4 weeks of the time that the first serum sample establish-
ing a decrease in albumin of >0.3 g/dL from the baseline
albumin concentration during the first study period was
obtained. If both values were ≥0.3 g/dL below the mean
base line value a second measurement of albumin synthe-
sis rate was carried out. In each case the average serum
albumin concentration value during the second period in
which albumin synthesis was measured was significantly
less than during the first period. In patients in whom no
such decrease occurred, a second measurement of albu-
min synthesis was conducted either after 2 years or at the
conclusion of the HEMO Study, whichever occurred first.
It should be noted that the ending of the HEMO Study re-
sulted in only one patient losing greater than 21/2 months
of potential follow-up time. Fifty-nine patients completed
both measurements. There were 20 patients who did not
complete both measurements and are not included in this
analysis. Of these, three were transplanted, 13 died, and
three were not studied a second time because they with-
drew from the study because either they moved out of
area or withdrew consent (one patient).
The time-to-event analysis, the results displayed in
Table 3, is the cleanest analysis of these data and pro-
vides a basis for predicting the time to a future decline
in albumin. This analysis also allows us to use all infor-
mation available, including from those patients who did
not remain in the study population so as to experience a
second study, treating these cases as censored at the time
dropout occurred.
From a clinical point of view, we should stress that an
early drop is generally worse than a late drop and that the
time-to-decline is over represented by patients who died
and underrepresenting by patients who left the study for
a subsequent transplant.
Finally, in the survival model, the partial likelihood
based tests are based on asymptotics, and there is a choice
of test statistics one can use. For testing the significance of
the predictors, we used Wald tests based on asymptotic
normality, where each is equivalent to an approximate
chi-square test with one degree of freedom. The sam-
ple size and number of events is not so small such that
these tests would be considered unreasonable.
During both 6-week periods, the first following en-
rollment, and the second either at the 2-year anniver-
sary of the first study, or following a decline in albumin
(see above) albumin turnover was measured [10]. Briefly,
10 lCi of [125]I human albumin was injected as a bolus
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and its disappearance from plasma was measured over
the 6 weeks. Albumin turnover rate, which at steady-
state is equal to the rate of albumin synthesis over that
6-week period could then be modeled kinetically [10].
Albumin turnover rate represents all albumin removal
from the body by all routs (i.e., albumin disappearance).
Since the plasma volume and plasma albumin mass are
calculated in the pharmacokinetic model [10, 18], the
fractional disappearance rate (FDR) can be calculated
as the fraction of the plasma albumin pool removed per
unit time, which we have chosen to report as percent per
day. Albumin disappearance is a consequence of both
catabolism and external loss. Since patients were essen-
tially anuric, the only measurable route for external albu-
min loss was across the dialyzer membrane. An aliquot
of dialysate was collected during each treatment during
the period when albumin synthesis was determined as
previously described for measurement of albumin syn-
thesis in dialysis patients [10, 18]. Since dialysis was only
performed three days a week, 3/7 of the total albumin
lost through dialysis was allocated as daily noncatabolic
losses of albumin, as described previously [18]. The resid-
ual albumin disappearance was then used to calculate
albumin FCR, which is calculated from the difference
between albumin turnover and albumin losses. Plasma
volume was established from an isotope dilution calcula-
tion. Plasma albumin mass (PAM) is the product of the
initial plasma volume and serum albumin concentration
measured during the first 3 hours of sampling. Total al-
bumin mass (TAM) is calculated kinetically as described
previously [10, 17–19] and uses all values of albumin de-
termined during the 6-week period of sampling. FCR is
the fraction of the PAM catabolized per 24-hour period
[10, 19, 20].
Laboratory methods
Serum albumin was measured using bromcresol green.
CRP, transferrin, ceruloplasmin and a1AG were each
measured initially and then weekly by rate nephelom-
etry using a Beckman Array automated nephelometer
(Beckman Instructions 015–248545–F; Beckman Instru-
ments, Inc., Brea, CA, USA). IL-6 was measured by
enzyme-linked immunosorbent assay (ELISA) (Hema-
gen Diagnostics, Columbia, MD, USA). All nephelomet-
ric measurements were made in duplicate in each of two
optical systems. All other proteins were measured in
serum. All measurements were made in duplicate. The
average of these values was used for calculations. The
intra-assay coefficient of variation (CV) for albumin was
0.22%, with an interassay ranging from 2.42% to 3.16%
over the usable range of the assay. The intra-assay CV for
a1AG was 0.14%, with an interassay CV ranging from
3.07% to 5.50% over the usable range of the assay. The
intra-assay CV for ceruloplasmin was 0.27%, with an in-
terassay CV ranging from 4.44% to 9.18% over the us-
able range of the assay. The intra-assay CV for trans-
ferrin ranged from 0.026% to 0.07%, with an interassay
CV ranging from 2.56% to 4.38%. enPCR was measured
monthly using a double pool method of urea kinetic anal-
ysis [21].
Statistical methods
During the first and second 6-week measurement pe-
riods for albumin synthesis, averages of enPCR and con-
centrations of various proteins were obtained for each of
the 59 patients previously described as experiencing both
measurements. First, we analyzed the changes in the av-
erage values of enPCR and measured proteins between
the two periods for each patient. The values of patients
who had a decrease in serum albumin were then com-
pared with values from patients with no change in serum
albumin. Paired t tests for changes were stratified based
on presence or absence of albumin decline.
The second phase of the analysis was to generate linear
regression models looking at what describes changes in
both albumin synthesis and albumin concentration. The
following two models were then generated (1) a model for
change in albumin synthesis rate for all 59 patients who
had two measurements and (2) a model for albumin con-
centration for all 59 patients who had two measurements.
Candidate predictors for these models included changes
between the first and second measurement periods of the
acute phase proteins, enPCR, plasma volume, FCR, and
PAM and TAM. Additional predictors included variables
available only at baseline, including body mass index, ac-
cess type, ethnicity, age, gender, and whether the patient
had diabetes as a cause of renal failure. These models used
all of the measures of enPCR and serum and plasma pro-
tein concentrations during the period from the beginning
of the first 6-week period during which albumin synthe-
sis was measured through the final measurement of the
second albumin synthesis period and thus included all of
the data rather than only the periods at the beginning and
end of observation.
A third regression model, a Cox proportional hazards
regression model [22] was run to predict time to albu-
min concentration decline. Only variables available at
baseline, including the baseline values (initial 6-week av-
erages) for the acute phase proteins, albumin synthesis,
were used for this model.
For the multiple linear regression models (Tables 1
and 2), we used a combination of all-subsets regression
and forward stepwise variable selection. For the survival
model (Table 3), we used only a forward variable selec-
tion approach.
Paired statistical analysis was used to compare base-
line levels of acute phase proteins and enPCR with
values measured during the second determination of
Kaysen et al: Inflammation and reduced albumin synthesis 1411
Table 1. Predictors of a change in albumin synthesis rate for all
patients
Standard
Variables Estimate error t value P value
(Intercept) 3.4556 0.9591 3.6031 0.0007
Change in plasma 0.0615 0.0107 5.7503 <0.0001
albumin mass
Change in total albumin 0.0120 0.0032 3.7647 0.0004
mass
Fractional catabolic rate 0.8211 0.0951 8.6318 0.0000
Access graft −0.7781 0.3787 −2.0547 0.0450
Access catheter −1.5021 0.6755 −2.2237 0.0306
Interleukin-6 −0.0305 0.0143 −2.1401 0.0372
Baseline synthesis rate −0.2193 0.0637 −3.4444 0.0012
Residual standard error, 1.312 on 51 degrees of freedom; multiple R2, 0.8847;
F statistic, 55.88 on 7 and 51 degrees of freedom, the P value is 0.
Table 2. Results for albumin concentration change model for all
patients
Standard
Variables Estimate error t value P value
(Intercept) 1.4673 0.3339 4.3946 0.0001
Change in a1 acid −0.0036 0.0008 −4.5825 0.0000
glycoprotein
Change in transferrin 0.0069 0.0010 6.7557 0.0000
Change in synthesis 0.0268 0.0076 3.5180 0.0009
rate
Time until second 0.00060 0.0001 4.2383 0.0001
study (in days)
Baseline albumin −0.4103 0.0792 −5.1825 0.0000
concentration
Residual standard error, 0.2071 on 53 degrees of freedom; multiple R2, 0.7806;
F statistic, 37.71 on 5 and 53 degrees of freedom; the P value is 2.22e-016.
albumin synthesis in the 21 patients in whom albumin
levels declined. Baseline and terminal values of albumin
synthesis PAM and TAM were also similarly analyzed.
Similar paired analysis was performed on the data from
the 38 patients in whom albumin levels did not decline.
All analyses were performed using the statistical pack-
age S-Plus 6.1 for Windows (Insightful Corporation,
2002).
RESULTS
Of the 59 patients who completed both studies, serum
albumin concentration decreased as defined by proto-
col in 21 patients and did not decline in the remaining
38 patients.
There were 28 women and 31 men. The mean age was
56.9 ± 14.2 years (median 59, range 19 to 81, 25th per-
centile 52, 75th percentile 67 years. Thirty-four patients
were African American, 11 Hispanic, nine Caucasian,
four Asian, and one Pacific Islander. Twenty patients
were diabetic, initial weight was 68.3 ± 14.3 kg (median
67, range 37 to 94 kg 25th percentile 58, 75th percentile
81 kg), initial body mass index (BMI) was 24.1 ± 4.4 (me-
dian 23.9, range 16.7 to 35.5, 25th percentile 21.2, 75th per-
centile 27.4), final weight was 68.9 ± 14.3 (median 66.5,
range 38.3 to 109.3, 25th percentile 57.7, 75th percentile
80 kg) final BMI mean 24.4 ± 4.3 (median 24.2 range 16.7
to 35.6, 25th percentile 21.8, 75th percentile 27.4) and vin-
tage at the time of the initial albumin study was 5.13 ±
3.65 years (median 4.67, range 0.67 to 20, 25th percentile
2.67, 75th percentile 6.33 years), the mean equilibrated
Kt/V was 1.37 ± 0.18, median 1.34, range 1.0 to 1.94,
the mean enPCR was 1.05 ± 0.24 g/kg, median 1.07,
range 0.47 to 1.81 g/kg, mean bicarbonate was 22.57 ±
3.43 mEq/L, median 23, range 13 to 30 mEq/L.
Among the patients in whom albumin declined, base-
line albumin was 4.33 ± 0.32 g/dL during the baseline
6-week period and declined to 3.82 ± 0.40 g/dL during
the final study period (P < 0.001). Among those patients
in whom there was no decline the baseline albumin level
was 4.23 ± 0.39 g/dL during the baseline period and was
4.36 ± 0.37 g/dL during the second study. This repre-
sented a significant increase in concentration (P = 0.008).
The median time between the two measurements was
21.8 months.
The average standard deviation of albumin values
for the stable patients during the baseline period was
0.363 ± 0.149 and during the second study was 0.341 ±
0.109. The average standard deviation of the albumin
values for the decliners during the baseline period was
0.357 ± 0.108 and during the second study during which
albumin had decreased was 0.342 ± 0.163. The variability
of albumin measurements during these periods was not
different among the four groups (P = 0.888).
Albumin synthesis rate was significantly reduced in
patients in whom albumin concentration declined by
0.3 g/dL but was unchanged in patients in whom al-
bumin concentration did not decline by this targeted
amount (Fig. 1). The levels of positive acute phase pro-
teins CRP (Fig. 2), ceruloplasmin and a1AG were all in-
creased significantly (P < 0.001 for each) in the patients
in whom albumin concentration decreased, but remained
unchanged in the patients in whom albumin levels did not
decrease by this target value (Fig. 3). Serum IL-6 level
also increased significantly in the patients in whom albu-
min declined (from 4.76 pg/mL (25th to 75th percentile
2.510–11.433 pg/mL) to 12.58 pg/mL (25th to 75th per-
centile 8.354 to 23.491 pg/mL) P < 0.001) but did not
change in the patients in whom albumin did not decline
(6.41 pg/mL (25th to 75th percentile 3.616 to 13.19 pg/mL)
to 7.09 pg/mL (25th to 75th percentile 3.767–12.109 pg/
mL) (P = 0.942).
The median value for dialysate albumin losses in the
patients in whom albumin levels declined was zero dur-
ing each period with a mean of 1.094 ± 2.351 g/treatment
(which is equivalent to a daily non catabolic loss of albu-
min of 0.469 ± 1.008 g/day for three treatments per week)
during the baseline period and 1.103 ± 2.488 g/treatment
(which is equivalent to a daily loss of 0.499 ± 1.072)
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Table 3. Results for model for time to albumin concentration drop
Standard
Expected error Lower Upper
Variables Coefficient (coefficient) (coefficient) t value P value 95% CI 95% CI
Age 0.0367 1.037 0.0167 2.19 0.028 1.004 1.072
Ethnicity −0.9267 0.396 0.4552 −2.04 0.042 0.162
Plasma albumin mass 0.0173 1.017 0.0087 1.99 0.047 1.000 1.035
Ethnicity = 1 for African Americans and = 0 for all others; R2 = 0.159 (max possible = 0.875); likelihood ratio test = 12.9 on 3 df, P = 0.00474.
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Fig. 1. Changes in the rate of albumin synthesis. Changes were mea-
sured as the turnover rate of [125]I human serum albumin measured
during a 6-week period at baseline and either after a decline in serum
albumin concentration of ≥0.3 g/dL (left panel) or following 2 years if
serum albumin concentration did not decline by 0.3 g/dL (right panel).
during the second period. There was also no difference
in dialysate loss per treatment in either period in either
group (i.e., the loss of albumin in dialysate in the pa-
tients with declining albumin was not significantly differ-
ent than was the loss of albumin during that same period
in the patients in whom albumin did not decline).
The median value for dialysate albumin losses in the
patients in whom albumin levels did not decline was also
zero for each period with a mean of 0.184 ± 0.563 g
per treatment during the baseline, a mean 0.0950 ±
0.246 g/day during the baseline period and again a me-
dian value of zero during the second study with a mean
of 0.0881 ± 0.389 g/treatment and of 0.0695 ± 0.252 g/day
during the second study.
Albumin FCR was unchanged in the patients in
whom albumin concentration did not decline (11.78% ±
2.51%/day in the first period vs. 11.69% ± 2.96%/day in
the second period) and also remained unchanged in the
decliners (11.13% ± 2.77%/day in the first period and
11.18% ± 3.35%/day in the second period). There were
no differences in FCR within any of these groups in any
period.
By stratifying patients on albumin decline status, we
researched the bivariate relationship between albumin
change and enPCR change. This can be seen in Figure 4,
where we can see both that average enPCR was no differ-
ent when the initial and terminal studies were compared
in either group (Fig. 4) and also when analyzed for the
entire data set, in which both decliners and stable pa-
tients were analyzed together over time. These observa-
tions suggest that the groups are not significantly different
from one another in terms of enPCR change over time.
A formal t test confirms this. This contrasts to what was
observed with regard to both acute phase proteins and
the cytokine IL-6.
Body weight also remained constant both in patients
having stable albumin concentrations [74.0 kg (25th per-
centile to 75th percentile 59.5 to 82.5 kg baseline to 67.95
(25th percentile to 75th percentile 59.6 to 81.5 kg during
the second study P = 0.317)] and in those in whom al-
bumin concentration declined [66 kg (25th percentile to
75th percentile 51.65 to 74.63 kg baseline to 64.50 (25th
percentile to 75th percentile 55.88 to 70.55 kg during the
second study P = 0.623)].
Both plasma albumin mass (137 ± 19.5 g/1.73 m2 to
118 ± 8.3 g/1.73 m2) (P < 0.05) and total albumin masses
(345 ± 12.30 g/1.73 m2 to 300 ± 15 g/1.73 m2) (P < 0.05)
decreased significantly in the subjects in whom albumin
concentration declined, but did not change in the subjects
in whom serum albumin concentration did not change.
The first regression, modeling change in albumin syn-
thesis for all 59 patients who experienced the first and
second measurement period, resulted in a model with the
following statistically significant predictors. A positive as-
sociation between a change in plasma albumin mass be-
tween first and second measurement periods and a change
in albumin synthesis rate, a positive association between
a change in TAM between first and second measurement
periods and a change in albumin synthesis rate, a positive
association between a change in albumin FCR between
first and second measurement periods and a change in
albumin synthesis rate, a negative association between
the presence of either a polytetrafluoroethylene (PTFE)
graft or a transcutaneous access at baseline, as compared
to arteriovenous fistula access, and subsequent change in
albumin synthesis rate (i.e., the presence of either a PTFE
graft or a transcutaneous access at baseline, as compared
to arteriovenous fistula access, was associated with a sub-
sequent decrease in albumin synthesis rate), a negative
association between baseline IL-6 and subsequent change
in albumin synthesis rate, and a negative association be-
tween baseline albumin synthesis rate and subsequent
change in albumin synthesis rate. Results are in Table 1.
Both residual plots and the model R2 suggest the model
fits well.
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Fig. 2. Changes in the levels of C-reactive
protein (CRP) (A), ceruloplasmin (B), and
a1 acid glycoprotein (a1AG) (C) in the 21
patients in whom albumin concentration de-
clined by ≥0.3 g/dL.
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Fig. 3. Levels of C-reactive protein (CRP)
(A), ceruloplasmin (B), and a1 acid glycopro-
tein (a1AG) (C) during the two periods during
which albumin synthesis was measured in the
38 patients in whom albumin concentration
did not change (stable).
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Fig. 4. Equalibrated normalized protein catabolic rate (enPCR) mea-
sured during the periods of determination of albumin synthesis rate
in the patients in whom albumin concentration declined by ≥0.3 g/dL
(A) and in those patients in whom albumin concentration remained
unchanged (B).
The second regression, modeling change in albumin
concentration for all 59 patients who experienced the first
and second measurement period, resulted in a model with
the following statistically significant predictors: A change
in albumin was negatively associated with a difference
in a1AG between first and second measurement period,
positively associated with a difference in transferrin be-
tween first and second measurement period, positively
associated with a difference in albumin synthesis rate be-
tween first and second measurement period, negatively
associated with baseline albumin concentration, and pos-
itively associated with a time to the second study. Results
are in Table 2. Both residual plots and the model R2 sug-
gest the model fits well (Table 2). The following are the
statistically significant predictors of a decrease in albu-
min: age, ethnicity (African American vs. non-African
American), and PAM.
The final regression model is the Cox proportional haz-
ards regression model to see what predictors available at
baseline were predictive of a shorter time to albumin con-
centration decline. The goal here is to find variables that
may help us predict a future drop in albumin. The follow-
ing are the statistically significant predictors: age, eth-
nicity, and PAM. That is, greater age, being non-African
American, and a greater baseline PAM was associated
with a shorter time to a decrease in albumin concentra-
tion (Table 3).
DISCUSSION
In those subjects with decreasing serum albumin con-
centration, there was a concomitant decrease in PAM and
TAM but no change in the PAM/TAM ratio. Hence, the
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decrease in serum albumin concentration was a conse-
quence of reduced PAM resulting from reduced albumin
synthesis, and was not a result of a stable shift of albumin
from the vascular to the extravascular pool, nor was it
a consequence of dilution resulting from plasma volume
expansion. It should be noted that the methods used in
this study were not sensitive enough to identify short-
term shifts in albumin from one compartment to another,
as a 6-week pharmacokinetic method was used to es-
tablish steady state distribution. We demonstrated a de-
crease in albumin synthesis providing a biologic basis for
decreased albumin concentration and mass. It should be
noted that others have found that additional or alternate
mechanisms suppress albumin levels during inflamma-
tory episodes [23], including increased albumin FCR. Our
observations here however are consistent with our previ-
ous small cross-sectional study in hemodialysis patients
[18].
What could cause the decrease in albumin synthesis?
Albumin synthesis can be suppressed by decreased pro-
tein intake [2, 12] or because of the acute phase response
[4]. Since IL-6 and all of the acute phase proteins we
measured increased significantly during the period in
which serum albumin concentration and synthesis rate
decreased, we conclude that inflammation is an impor-
tant factor causing a decrease in albumin synthesis and
ultimately, a decrease in serum albumin concentration
and PAM. This view is supported by our finding that the
serum concentration of another negative acute phase pro-
tein, transferrin levels was also positively associated with
albumin concentration.
In these analyses, we did not quantify the actual intake
of protein or calories nor did we change dietary protein
or calories. Instead, we used the enPCR value from urea
kinetics. It assumes steady-state conditions and implies
that nitrogen appearance is an estimate of nitrogen in-
take [24, 25]. We found no significant decrease in enPCR
of the group as a whole or in those patients who expe-
rienced a fall in serum albumin. Thus, the influence of
enPCR on the albumin levels must be quite small unless
there is inflammation or some other illness [3, 7, 15]. Ad-
ditionally, there was no significant change in body weight
in either patients having a stable albumin concentration
or in those in whom albumin concentration declined. In
short, the evidence that the acute phase response is asso-
ciated with reduced albumin synthesis and hence a lower
serum albumin concentration and there is no evidence
that decreased enPCR plays any significant role in the de-
velopment of hypoalbuminemia or in the decrease in al-
bumin synthetic rate. While enPCR may not be identical
to protein intake during periods when protein catabolism
exceeds that of protein intake, the lack of any significant
difference in body weight also supports our contention
that this was not the case. As pointed out recently, the
diagnosis of malnutrition as the sole cause of a low serum
albumin in hemodialysis patients would only rarely be
appropriate [14].
We initially concluded that suppression of albumin syn-
thesis was the cause of hypoalbuminemia following eval-
uation of a small group of hemodialysis patients who had
serum albumin levels >4 g/dL or <3.5 g/dL [18]. In that
study as well, we found no evidence for an important
influence of nutritional factors as a cause of a low serum
albumin. However, that was a cross-sectional analysis and
hence, there was minimal ability to strengthen the associ-
ations uncovered by determining whether the presence of
a condition (e.g., inflammation) would be predictive of a
change in albumin synthesis rate. In the present study, we
examined dialysis patients longitudinally and were able
to determine when serum albumin decreased, what was
the contemporaneous albumin synthesis rate, and how
these values were related to evidence of inflammation or
changes in diet as reflected by enPCR.
enPCR at steady-state should reflect net protein
catabolism and be associated with dietary protein intake.
During the course of the HEMO Study enPCR decreased
over time [abstract; Rocco M, et al, J Am Soc Nephrol
13:421A. 2002]. While that value was statistically signifi-
cant for the HEMO group as a whole, the change in en-
PCR did not approach significance in our much smaller
group. Of importance, the change in enPCR was not as-
sociated with a change in albumin for our entire cohort
of patients, and the enPCR values measured during each
of the periods in which albumin synthetic rate was mea-
sured were not significantly different. Additionally there
was no difference between those patients in whom albu-
min levels fell and in those in whom it did not. These
findings suggest that if enPCR is associated with albumin
synthesis rate the effect is quite small. These findings are
compatible our previous cross sectional observations on
a much smaller group [18]. The apparent lack of an inde-
pendent effect of nutrition on albumin levels is also com-
patible with studies in patients with anorexia nervosa [3].
Malnutrition alone, except preterminally [3], has very lit-
tle effect on plasma protein composition. It is the combi-
nation of both malnutrition and inflammation that effects
the greatest change [26, 27].
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